GlassScriptPhysician profile
Muhammad G Alam
NPI 1932202819
$2,110.60
in general payments reported to CMS, 2019-2025
21 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $219 · 2021: $400 · 2022: $283 · 2023: $183 · 2024: $407 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.13 |
| Education | $102.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $288.63 | 2023-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $254.90 | 2020-2024 | Acthar |
| Fresenius USA Marketing, INC. | $246.47 | 2019-2023 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $227.21 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $202.07 | 2020-2024 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $157.84 | 2019-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $119.71 | 2022-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $106.56 | 2020-2023 | Rayaldee |
| Amgen INC. | $97.58 | 2022-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $66.92 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $62.84 | 2019 | |
| Calliditas Therapeutics US INC. | $43.02 | 2023-2024 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $41.72 | 2021-2024 | Crysvita |
| Vifor Pharma, INC. | $39.69 | 2020-2021 | |
| Horizon Therapeutics Plc | $29.87 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $28.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.98 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.52 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.08 | 2019 | |
| Kyowa Kirin, INC. | $15.06 | 2025 | |
| Merck Sharp & Dohme LLC | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.